# **Special Issue**

## Vaccine Against Sexually Transmitted Diseases

### Message from the Guest Editor

This Special Issue, entitled "Vaccine Against Sexually Transmitted Diseases", of Vaccines highlights cuttingedge research and innovative strategies aimed at combating sexually transmitted infections (STIs) through vaccination. It features breakthroughs in vaccine development, targeting prevalent STIs such as human papillomavirus (HPV), HIV, syphilis, gonorrhea, and chlamydia. This Special Issue emphasizes the importance of preventive measures, equitable access to vaccines, and the integration of vaccination programs into public health initiatives. By showcasing interdisciplinary collaborations and emerging technologies, this Special Issue aims to foster dialogue among researchers, clinicians, and policymakers to enhance global health outcomes and reduce the burden of STIs.

#### **Guest Editor**

Dr. Weiming Tang

- 1. Institute for Global Health and Infectious Diseases, University of North Carolina at Chaple Hill, Chapel Hill, NC 27599, USA
- 2. Institute for Global Health and Sexually Transmitted Diseases, Southern Medical University, Guangzhou 510315, China

### Deadline for manuscript submissions

closed (30 September 2025)



an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/217877

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

#### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

#### **Author Benefits**

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

#### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

